DIBI (Topical)

About Fe Pharmaceuticals

Fe Pharmaceuticals is a private, preclinical-stage biotech leveraging a novel platform of iron-binding polymers to treat diseases driven by iron dysregulation. Its lead candidate, DIBI, is designed to sequester iron from pathogens and rapidly dividing cells, with initial applications targeting antimicrobial-resistant infections, sepsis, and cancer. The company's approach represents a unique, non-antibiotic mechanism to address growing global threats like AMR, with a versatile pipeline spanning inhaled, IV, oral, and topical formulations.

Therapeutic Areas